Central DuPage Hospital

Summary

Central DuPage Hospital is a medical facility located in Winfield, Illinois. This center is recognized for care of Stroke, Parkinson's Disease, Ovarian Cancer, Atrial Fibrillation, Heart Failure and other specialties. Central DuPage Hospital is involved with conducting 67 clinical trials across 156 conditions. There are 12 research doctors associated with this hospital, such as David O. Walterhouse, Jennifer L. Reichek, Sara Zarnegar-Lumley, MD, and Jenna Rossoff, MD.

Top PIs

Clinical Trials running at Central DuPage Hospital

Stroke

Atrial Fibrillation

Rhabdomyosarcoma

Cancer

Osteosarcoma

Obesity

Melanoma

Desmoid Tumor

Neuroendocrine Tumors

Appendicitis

Thrombectomy + Angioplasty/Stenting

for Stroke

This trial tests if using a stent to open a blocked neck artery along with removing a brain clot is better than just removing the clot alone for stroke patients with severe artery blockages.

Recruiting

2 awards

Phase 3

12 criteria

Left Atrial Appendage Occlusion vs. NOAC

for Atrial Fibrillation

The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. The clinical investigation is a prospective, randomized, multicenter active control worldwide trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device ("Device Group") and a commercially available NOAC medication ("Control Group"). The choice of NOAC in the Control Group will be left to study physician discretion.

Recruiting

1 award

N/A

8 criteria

Recombinant Factor VIIa

for Hemorrhagic Stroke

The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy. FASTEST Part 2 is an extension of the FASTEST Trial where the subgroups include only those treated within 2 hours with a positive spot sign on a baseline CT angiogram.

Recruiting

1 award

Phase 3

2 criteria